Algeta ASA has appointed Lars Abrahmsén to the new post of senior vice president, protein therapeutics, with responsibility for developing the company’s alpha pharmaceutical platform for cancer which is based on thorium 227. Dr Abrahmsén was previously chief scientific officer at Affibody AB of Sweden. He has worked in the areas of protein engineering, including monoclonal antibody production and conjugation, at Affibody, Genentech (now Roche) and Pharmacia (now Pfizer) where he established the companies’ phage display and antibody cloning capabilities.
Copyright 2010 Evernow Publishing Ltd